Neuren Pharmaceuticals Limited · ASX:NEU
Neuren Pharmaceuticals — Boston Bio-Relationships Conference, eG Capital Australian Bio-Investment Forum, Bio 2006
20 slides from Neuren Pharmaceuticals's conference presentation, Apr 4, 2006
Slide 1: Neuren Presentation to US Conferences
pharmaceuticals Neuren Presentation to US Conferences 4 April 2006: The Chief Executive Officer of Neuren Pharmaceuticals Limited (ASX:NEU), Mr David Clarke, has been invited to speak at the Boston Bio-Relationships Conference, eG Capital's Australian Bio-Investment Forum in New York, and the Bio 20
Slide 2: Neuren Pharmaceuticals Update
Neuren Pharmaceuticals Update New York April 2006
Slide 3: Disclaimer
Disclaimer This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Neuren to be materially different from the statements
Slide 4: Corporate Overview
Neuren Pharmaceuticals Corporate Overview
Slide 5: Corporate Overview
Corporate Overview Neuren is a drug development company targeting Neuronz Ltd: 11.0% brain repair& rescue, metabolism and cancer NZ Seed Fund Management Ltd: 10.2% Neuren’s lead products protect against brain damage, fas 9, with two NCE’s in Human Trials (Phase 2 and Phase 1) Macquarie: 8.6% Gi e@ h
Slide 6: Recent Events
Recent Events = Strong cash position =» NEU has two ACUTE CNS trials underway — Pre-clinical Glypromate work for Phase 3 completed - Phase 2a report finalised « Glypromate Phase 3 on target « IND filing in September —- Excellent pre-clinical results for IV administration of NNZ-2566 = NEU has two dr
Slide 7: Development Pipeline
Development Pipeline + Glypromate® + NNZ-2566 (iv) CNS Product ; Portfolio * MC’s + Cancer Growth Hormone (GH) . ob Amerie - . ce Portfolio Two in clinic , four in pre-clinical, two discovery programmes Extensive development portfolio offering several means of delivering value 6 neuren hareanitannle
Slide 8: Glypromate®
Glypromate® « Glypromate® is derived from a naturally occurring peptide that is generated by the human brain. ® Glypromate® has the following significant neuroprotection characteristics: ~- Safe....maximum feasible dose ..no maximum tolerated dose - Crosses the blood brain barrier (BBB) - Multiple m
Slide 9: Glypromate® - Neuroprotection in CABG Surgery
Glypromate® - Neuroprotection in CABG Surgery = Coronary Artery Bypass Graft (CABG) surgery was selected by Neuren because of its drug trial characteristics and excellent commercial prospects: j. Drug Trial Characteristics + CABG surgery scheduling is timed and known - Up to 70% of patients have a d
Slide 10: Glypromate® — Development Plan
Glypromate® — Development Plan CY 2005 iE -OCT 2005 Phase 1 completed in Oct 2005 + Demonstrated excellent safety profile in 30 healthy patients CY 2006 > @ Major Milestone MAR/APR 2006 Commenced Phase 2a in Dec 2005 assessing the safety profile in 30 CABG patients * Data available end Apr AUG/SEP 2
Slide 11: Glypromate® — Accelerated into Phase 3
Glypromate® — Accelerated into Phase 3 2 Safety is the key issue governing whether Glypromate® will successfully enter Phase 3 in 2006 = Safety considerations have been paramount in design and conduct of Phase 2a trial and preparation for Phase 3 = All the evidence to date suggests that Glypromate®
Slide 12: NNZ-2566 — First Indication is Traumatic Brain Injury
NNZ-2566 — First Indication is Traumatic Brain Injury Co-development with US Army (Walter Reed, Washington) ~ Share costs ..But NEUREN 99% market ~ 2566 domain is completely partnerable NN2Z-2566 offers additional attractive characteristics including: 1. Longer acting 2. Oral bioavailability- chroni
Slide 13: NNZ-2566 has Delivered Excellent Results to Date
NNZ-2566 has Delivered Excellent Results to Date s Very successful pre-clinical program with Walter Reed - 70% reduction in neurological deficit at 72 hours — 50% reduction in activated microglia (key element of inflammation) » Neuren and Walter Reed have identified a new and effective measure for a
Slide 14: NNZ 2566 Flexibility
NNZ 2566 Flexibility = Toxicity package allows other acute iv markets ~ Hemorrhagic stroke * Market potential (US) US$800 million + Similar pathology to TBI » NNZ 2566 strong in-vivo results ~ Stroke recovery + Market est. US$2 billion » In hospital post stroke » In vivo results Uni Texas = And.....
Slide 15: NNZ 2566 Development Plan
NNZ 2566 Development Plan CY 2005 1 CY 2006 > Complete pre-clinical program wit! Walter Reed « Demonstrated excellent results in all animal studies to date @ Major Milestone . Delivered GMP for drug manufacturing Commence Phase 1 in 1H 2006 + Cost of goods reduced by « Alfred hospital (Melbourne) 75
Slide 16: Pipeline
Pipeline Opportunity to out-license four product lines in near ferm
Slide 17: Four Near Term Out licensing Opportunities
Four Near Term Out licensing Opportunities = NEU does not have the resources to independently develop its entire pipeline « NEU has focused on developing four product lines such that they are attractive near-term out-licensing opportunities ~ Stable compounds ~ Excellent manufacturing characteristic
Slide 18: Conclusion: Poised for major milestones
(neuren ) pha rina Conclusion Poised for major milestones
Slide 19: Investment highlights- All on Track as per Dec
Investment highlights- All on Track as per Dec 05 Stage of Development Poised for Major Milestones Excellent Commercialisation Prospects Strategic Fiexibilit Glypromate® accelerated to Phase 3 in CY2006 ~ Preclinical package completed... SAFE and STABLE NNZ 2566 Phase 1 in 1H CY2006 and will deliver
Slide 20: Investment highlights
Investment highlights Uniquely positioned to fund lis own Phase 3 Study Significant Market Opportunities . Excellent Management Team bd Breadth and qualiiy of portfolio Very few Australian companies are in Phase 3 trials: Typically prohibitively expensive Neuren in close consultation with the US FDA